ATE336509T1 - Verwendung von taci als antitumormittel - Google Patents

Verwendung von taci als antitumormittel

Info

Publication number
ATE336509T1
ATE336509T1 AT01927474T AT01927474T ATE336509T1 AT E336509 T1 ATE336509 T1 AT E336509T1 AT 01927474 T AT01927474 T AT 01927474T AT 01927474 T AT01927474 T AT 01927474T AT E336509 T1 ATE336509 T1 AT E336509T1
Authority
AT
Austria
Prior art keywords
taci
mammal
antitumor agent
reagent
administering
Prior art date
Application number
AT01927474T
Other languages
English (en)
Inventor
Christine Ambrose
Jeffrey Thompson
Pascal Schneider
Paul Rennert
Original Assignee
Biogen Idec Inc
Apoxis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Apoxis Sa filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE336509T1 publication Critical patent/ATE336509T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01927474T 2000-04-27 2001-04-27 Verwendung von taci als antitumormittel ATE336509T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19994600P 2000-04-27 2000-04-27

Publications (1)

Publication Number Publication Date
ATE336509T1 true ATE336509T1 (de) 2006-09-15

Family

ID=22739664

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927474T ATE336509T1 (de) 2000-04-27 2001-04-27 Verwendung von taci als antitumormittel

Country Status (13)

Country Link
EP (1) EP1297013B1 (de)
JP (1) JP2004513876A (de)
AT (1) ATE336509T1 (de)
AU (2) AU5392001A (de)
CA (1) CA2404945C (de)
CY (1) CY1105788T1 (de)
DE (1) DE60122337T2 (de)
DK (1) DK1297013T3 (de)
ES (1) ES2271004T3 (de)
NZ (1) NZ521629A (de)
PT (1) PT1297013E (de)
SI (1) SI1297013T1 (de)
WO (1) WO2001081417A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
WO2002094852A2 (en) * 2001-05-24 2002-11-28 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
KR20120053525A (ko) * 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
EP2270040A3 (de) 2000-08-18 2011-07-06 Human Genome Sciences, Inc. Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
AU2002215753A1 (en) * 2000-12-07 2002-06-18 The University Of British Columbia Caml-binding peptides
WO2002094192A2 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
EP1629001A2 (de) 2003-06-05 2006-03-01 Genentech, Inc. Blys-antagonisten und deren verwendung
CA2554526A1 (en) 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
EP1922080A2 (de) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Verfahren zur behandlung von b-zell-malignomen mittels taci-ig-fusionsmolekül
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
BRPI0711823A2 (pt) * 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
CN101323643B (zh) * 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
ES2565202T3 (es) 2007-10-16 2016-04-01 Zymogenetics, Inc. Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US11517591B2 (en) * 2017-09-01 2022-12-06 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens
MX2022013998A (es) 2020-05-08 2023-02-16 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
ATE437227T1 (de) * 1999-01-07 2009-08-15 Zymogenetics Inc Verfahren zur therapeutischen verwendung von löslichen rezeptoren br43x2
AU3633000A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon

Also Published As

Publication number Publication date
JP2004513876A (ja) 2004-05-13
WO2001081417A2 (en) 2001-11-01
NZ521629A (en) 2004-05-28
DE60122337D1 (de) 2006-09-28
CA2404945C (en) 2010-02-09
AU2001253920B2 (en) 2006-03-16
PT1297013E (pt) 2006-12-29
SI1297013T1 (sl) 2007-06-30
DE60122337T2 (de) 2007-08-16
AU5392001A (en) 2001-11-07
DK1297013T3 (da) 2006-12-27
ES2271004T3 (es) 2007-04-16
WO2001081417A3 (en) 2002-06-20
CA2404945A1 (en) 2001-11-01
CY1105788T1 (el) 2011-02-02
EP1297013A2 (de) 2003-04-02
EP1297013B1 (de) 2006-08-16

Similar Documents

Publication Publication Date Title
ATE336509T1 (de) Verwendung von taci als antitumormittel
ATE441418T1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
NO20060600L (no) Spesifikke bindingsmidler for hepatocytt vekstfaktorer
TR200102800T2 (tr) Yeni bileşikler.
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
ES2186874T3 (es) Analogos de m-amidinofenilo como inhibidores del factor xa.
GEP20063937B (en) Substituted pyridinones as modulators of p38 map kinase
ATE246197T1 (de) Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
ATE363280T1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
CR6393A (es) Moduladores de ccr5
PL2274373T3 (pl) Mieszaniny zmiatające tlen
LT2004074A (en) Matricines metalproteinazes inhibuojanti kompozicija neoplazinems ligoms gydyti
SE0400208D0 (sv) Chemical compounds
BRPI0410512A (pt) processo que compreende o contato de po3g e composição que compreende (i) po3g
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis
BRPI0512310A (pt) compostos quìmicos
DE50114181D1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan-verbindungen zur therapie der harninkontinenz
ID28892A (id) Sintesa heteropoliasida
ES2097798T3 (es) Reactivo oxidable productor de color.
TR200000624T2 (tr) Bir enzimin etkinliğinin arttırılması ile ilgili bir yöntem.
ATE277060T1 (de) 1,5-anhydro-d-fruktose substituiert mit einer hydrophoben gruppe zur verwendung als antioxidant und/oder emulgator
DE69719218D1 (de) Verwendung von pvp oder povidone zum reduzieren von darmschwellungen
EA200200160A1 (ru) Аналоги псевдомицина с n-ацильной боковой цепью
ATE238791T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1297013

Country of ref document: EP